Credit Suisse Ag Aeglea Bio Therapeutics, Inc. Transaction History

Credit Suisse Ag

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	BUY	$0.5 - $2.66 $10 - $55	21 New	21 $0
Q1 2021 May 14, 2021	SELL	$6.76 - $8.57 $78,443 - $99,446	-11,604 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$7.02 - $9.83 $81,460 - $114,067	11,604 New	11,604 $91,000

241K

Ticker AGLE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,172,500
Market Cap $1.69B
Description
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy f...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.